Want to see SDGR full AI Analyst Report?
Revenue by Type
Separates revenue into product, services, subscription, license, milestone, and royalty streams so you can see which parts drive growth and margins. Heavy product/subscription revenue signals scalable, repeatable income, while concentration in milestone or one-time fees increases volatility and makes forecasts less reliable.Software revenue is transitioning from lumpy, year‑end license peaks to steadier ratable hosted recognition — that supports ACV growth but depresses near‑term reported revenue and software gross margins as customers migrate. Meanwhile drug‑discovery receipts have surged thanks to accelerated collaboration recognition, giving a meaningful but inherently lumpy lift while contribution revenue has largely disappeared. Management’s maintained ACV guidance, hosted roadmap and upcoming AI product point to stronger recurring monetization long term, but expect near‑term revenue timing volatility and margin compression.
Date | Software Products and Services | Drug Discovery | Contributions |
|---|---|---|---|
Jun 30, 2026 | $32.54M | $22.99M | $3.36M |
Mar 31, 2026 | $35.56M | $23.03M | $0.00 |
Dec 31, 2025 | $69.28M | $17.95M | $0.00 |
Sep 30, 2025 | $40.86M | $13.47M | $0.00 |
Jun 30, 2025 | $40.54M | $14.21M | $0.00 |
Mar 31, 2025 | $48.82M | $10.73M | $0.00 |
Dec 31, 2024 | $79.70M | $8.70M | $0.00 |
Sep 30, 2024 | $31.88M | $3.41M | $0.00 |
Jun 30, 2024 | $35.40M | $11.93M | $0.00 |
Mar 31, 2024 | $33.41M | $3.18M | $0.00 |